Methods for treating and diagnosing blinding eye diseases
This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
1. A method for treating dry age related macular degeneration (AMD) or reticular pseudodrusen (RPD) disease, comprising administering to a subject in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
each of R 1 and R 2 is independently H or a C1-C6 alkyl and
R 3 is H or a C1-C6 alkyl.
2. The method of claim 1 , wherein the compound of Formula I is bindarit.
3. The method of claim 1 , wherein the dry AMD is early stage AMD or atrophic AMD.
4. The method of claim 1 , wherein the method reduces the rate of progression to late disease.
5. The method of claim 1 , wherein the method reduces the rate of expansion of geographic atrophy.
6. The method of claim 1 , wherein the method comprises reducing the amount of pseudodrusen in the subject.
7. The method of claim 6 , wherein the method comprises reducing the amount of pseudodrusen in any one of the foveal area, perifoveal area, and juxtafoveal area of the subject's eye.
8. The method of claim 6 , wherein the reduction in the amount of pseudodrusen in the subject is assessed using optical coherence tomography (OCT).
9. The method of claim 1 , wherein the method comprises reducing expansion of pseudodrusen in the subject.
10. The method of claim 9 , wherein the method comprises reducing expansion of pseudodrusen in any one of the foveal area, perifoveal area, and juxtafoveal area of the subject's eye.
11. The method of claim 1 , wherein the method further comprises administering an additional therapeutic agent.
12. The method of claim 11 , wherein the additional therapeutic agent is one or more of an anti-vascular endothelial growth factor (VEGF) agent, an angiotensin-converting enzyme (ACE) inhibitor, a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, a renin inhibitor, a steroid, and an agent that modulates autophagy.
13. The method of 2 , wherein the bindarit is formulated for sustained release.
14. A method for reducing the rate of expansion of geographic atrophy in an eye of a subject afflicted with dry age related macular degeneration (AMD), comprising administering to the subject an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
each of R 1 and R 2 is independently H or a C1-C6 alkyl and
R 3 is H or a C1-C6 alkyl.
15. The method of claim 14 , wherein the compound of Formula I is bindarit.
16. The method of 15 , wherein the bindarit is formulated for sustained release.